Impact of six rounds of national drug price negotiation on availability, cost, use, and prices of targeted drugs in China

Evidence supports the claim that the Policy achieved its desired objectives, although there is a valid case for increasing the availability of medicines and establishing availability assessment criteria for innovative drugs. We recommend that the government be more sensitive to abnormal changes in drug prices and patient costs after the end of the negotiated agreement period.